Back to Search Start Over

An updated methodology to review developing-country vaccine manufacturer viability

Authors :
Nicholas, Luter
Ritu, Kumar
Dai, Hozumi
Tina, Lorenson
Shannon, Larsen
Bhavya, Gowda
Amie, Batson
Source :
Vaccine
Publication Year :
2016

Abstract

Highlights • 8 factors predict the viability of vaccine manufacturers in developing countries. • These factors have evolved as the vaccine landscape has changed over 2 decades. • A new analysis updates a framework first published in 1997 to assess viability. • The updated framework is useful for assessing investments in vaccine manufacturers.<br />In 1997, Milstien, Batson, and Meaney published “A Systematic Method for Evaluating the Potential Viability of Local Vaccine Producers.” The paper identified characteristics of successful vaccine manufacturers and developed a viability framework to evaluate their performance. This paper revisits the original study after two decades to determine the ability of the framework to predict manufacturer success. By reconstructing much of the original dataset and conducting in-depth interviews, the authors developed informed views on the continued viability of manufacturers in low- and middle-income country markets. Considering the marked changes in the market and technology landscape since 1997, the authors find the viability framework to be predictive and a useful lens through which to evaluate manufacturer success or failure. Of particular interest is how incumbent and potentially new developing-country vaccine manufacturers enter and sustain production in competitive international markets and how they integrate (or fail to integrate) new technology into the production process. Ultimately, most manufacturers will need to meet global quality standards to be viable. As governments and donors consider investments in vaccine producers, the updated viability factors will be a useful tool in evaluating the prospects of manufacturers over the mid to long term. The paper emphasizes that while up-front investments are important, other critical factors—including investments in a national regulatory authority, manufacturer independence, and ability to adapt and adopt new technology—are necessary to ensure viability.

Details

ISSN :
18732518
Volume :
35
Issue :
31
Database :
OpenAIRE
Journal :
Vaccine
Accession number :
edsair.pmid..........041a1d3f849ac481a24a2d2a92c29953